Higlance Laboratories Private Limited

Higlance Laboratories Private Limited, established on June 11, 2003, is a privately held pharmaceutical company headquartered in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U24239DL2003PTC120847. With an authorized and paid-up capital of ₹6.00 crore, Higlance Laboratories operates as a non-government, unlisted entity.

The company employs approximately 386 professionals as of March 31, 2024. Higlance Laboratories specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to various therapeutic categories. Their product portfolio encompasses anti-diabetic, antimycobacterial, antibacterial, antifungal, antiseptic, antihelmintic, antiprotozoal, antihistamine, anti-inflammatory, analgesic, cardiovascular, cough and cold, and gastrointestinal medications.

Higlance Laboratories operates a manufacturing plant located in Greater Noida, India. The facility is equipped to produce a diverse range of pharmaceutical products, including tablets, capsules, and soft gelatin capsules. In 2019, the company expanded its production capabilities by establishing a new facility dedicated to soft gelatin capsules, enhancing its manufacturing capacity and product offerings.

The leadership team at Higlance Laboratories comprises:

• Sanjay Kumar Singh – Managing Director
• Ajay Singh – Whole-Time Director
• Kalawati Devi – Director

These individuals have been instrumental in steering the company's strategic direction and operational growth since its inception.

Higlance Laboratories has made significant strides in expanding its presence in regulated markets:

• United States: The company has initiated the process of obtaining approvals for its products, aiming to enter the U.S. market.

• European Union: Higlance Laboratories is in the process of obtaining approvals for its products, targeting entry into the EU market.

• United Kingdom: The company is working towards obtaining approvals for its products, with plans to enter the UK market.

• Australia: Higlance Laboratories is in the process of obtaining approvals for its products, aiming to enter the Australian market.

• Japan: The company is working towards obtaining approvals for its products, targeting entry into the Japanese market.

These efforts reflect Higlance Laboratories' commitment to expanding its global footprint and adhering to international regulatory standards.

Higlance Laboratories has strategically penetrated emerging markets, including Africa, Latin America, and Southeast Asia. The company's participation in international exhibitions and conferences, such as the Research Society for the Study of Diabetes in India (RSSDI 2019) and the Cardiological Society of India (CSICON 2019), underscores its commitment to global outreach and market expansion.

Higlance Laboratories has adopted a diversified geographic strategy, focusing on both developed and emerging markets. While the company has a strong presence in India, it is actively pursuing expansion into regulated markets like the U.S., EU, UK, Australia, and Japan. Additionally, its engagement in emerging markets demonstrates a balanced approach to mitigate concentration risk and leverage growth opportunities across different regions.

As of March 2026, Higlance Laboratories is in the process of obtaining approvals for its products from the U.S. Food and Drug Administration (FDA). The company has initiated the filing of Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs) to meet FDA requirements. While specific details regarding FDA facility registrations and inspection history are not publicly disclosed, the company's proactive approach indicates a commitment to adhering to FDA standards.

Higlance Laboratories is in the process of obtaining approvals for its products from the World Health Organization (WHO) and the European Medicines Agency (EMA). The company is working towards obtaining WHO prequalification and EU Good Manufacturing Practice (GMP) certificates to ensure compliance with international quality standards.

In India, Higlance Laboratories holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers. The company has obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating its international trade operations.

As of March 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Higlance Laboratories by regulatory authorities. This absence suggests a favorable compliance history, although specific details may not be publicly disclosed.

Higlance Laboratories operates in a competitive pharmaceutical market, facing competition from both domestic and international companies. While specific market share data is not publicly available, the company's focus on diverse therapeutic categories and international expansion positions it to effectively compete in various segments.

Higlance Laboratories distinguishes itself through its commitment to quality and innovation. The development of "Dispersion Technology" for calcium combinations, ensuring early absorption and faster dissolution with a pleasant orange flavor, exemplifies the company's focus on enhancing product efficacy and patient compliance.

Higlance Laboratories is strategically positioned as a research-driven pharmaceutical company, focusing on the development and manufacturing of generic medications across various therapeutic areas. The company's future outlook includes expanding its product portfolio, enhancing manufacturing capabilities, and increasing its presence in both regulated and emerging markets.

Higlance Laboratories has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products. The company's export volume and consistency reflect its reliability as a supplier. However, specific reliability indicators are not publicly disclosed.

Importers should verify the following certifications when considering Higlance Laboratories as a supplier:

• FDA Approval: Confirm the company's FDA facility registrations and approved ANDAs.

• WHO-GMP Certification: Ensure the company holds WHO prequalification for its products.

• EU GMP Certification: Verify the company's compliance with EU Good Manufacturing Practices.

• ISO Certification: Check for relevant ISO certifications related to quality management systems.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from the company.

When conducting due diligence on Higlance Laboratories, consider the following steps:

• Regulatory Compliance: Verify the company's compliance with FDA, WHO, EU GMP, and ISO standards.

• Financial Health: Review the company's financial statements for profitability and stability.

• Product Quality: Assess the quality control measures and product testing protocols in place.

• Supply Chain Reliability: Evaluate the consistency and reliability of the company's supply chain operations.

Be cautious of red flags such as unresolved regulatory issues, financial instability, or inconsistent product quality. Recommended pre-order checks include obtaining recent regulatory certificates, financial audits, and product samples for quality assessment.